Related Experiment Videos
Immunosuppressive drug therapy for rheumatic disease
1University of Michigan Medical Center, Ann Arbor.
Current Opinion in Rheumatology
|June 1, 1991
Summary
Intravenous cyclophosphamide offers no advantage over oral forms for most rheumatic diseases. Azathioprine is effective for Beçhet
Area of Science:
- Immunopharmacology
- Rheumatology
- Nephrology
Background:
- Review of immunosuppressive agents including cyclophosphamide, azathioprine, nitrogen mustard, and cyclosporine.
- Focus on intravenous (IV) versus oral administration routes.
- Examination of complications associated with these therapies.
Purpose of the Study:
- To review the use and complications of specific intravenous immunosuppressive agents.
- To evaluate the comparative efficacy of IV versus oral cyclophosphamide in rheumatic diseases.
- To assess the role of azathioprine and cyclosporine in specific autoimmune conditions.
Main Methods:
- Literature review of studies on cyclophosphamide, azathioprine, nitrogen mustard, and cyclosporine.
- Analysis of comparative trials for intravenous versus oral cyclophosphamide.
- Examination of clinical data regarding azathioprine in Beçhet's disease.
- Review of dose-efficacy and dose-toxicity data for cyclosporine in rheumatoid arthritis.
Main Results:
- No demonstrated superiority of IV over oral cyclophosphamide in rheumatic diseases, except for systemic lupus erythematosus.
- Azathioprine identified as a beneficial immunosuppressive therapy for Beçhet's disease.
- Cyclosporine's efficacy and toxicity in rheumatoid arthritis are directly related to dosage levels.
Conclusions:
- Intravenous cyclophosphamide is not superior to oral administration for most rheumatic conditions.
- Azathioprine is a valuable treatment option for Beçhet's disease.
- Cyclosporine dosing requires careful management in rheumatoid arthritis due to dose-dependent effects.